鲁他卡因诱导CYP1A2而加剧了乙胺诱导的急性肝损伤
Meiqi Wan1, Hua Gao1, Xiaoyan Liu2
1State Key Laboratory of Natural and Biomimetic Drugs, Key Laboratory of State Administration of Traditional Chinese Medicine for Compatibility Toxicology, Department of Natural Medicines, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
Toxics
|July 26, 2024
概括
鲁他卡因增加CYP1A2代谢,产生有毒中间体而加剧了乙氨基诱导的肝损伤. 这凸显了在药物开发中需要谨慎剂量,以避免严重的肝炎.
科学领域:
- 药理学 药理学是指药理学的学科.
- 肝病学 肝病学是一种肝病学.
- 毒理学 毒理学 毒理学
背景情况:
- 乙氨基过量服用是导致急性肝衰竭的主要原因.
- 鲁他卡是一种传统草药成分,具有潜在的药物相互作用.
- 鲁他卡和乙氨基的肝毒性之间的相互作用尚不清楚.
研究的目的:
- 实验室和体内的活体中,调查路他卡是否会加剧乙氨基引起的急性肝损伤.
- 阐明这种相互作用的潜在分子机制.
主要方法:
- 细胞活力 (CCK-8) 和亡试验用于评估乙氨基的细胞毒性.
- 西部涂抹和qRT-PCR确定了蛋白质和基因表达水平.
- 血素和氨酸染色评估肝脏病理,血AST/ALT水平测量肝脏损伤.
主要成果:
- 在细胞和小鼠中,ruecarpine预治疗显著恶化了乙氨基诱导的肝损伤.
- 鲁泰卡尔宾诱导了CYP1A2的表达,加速了乙氨基的代谢转化为有毒中间体NAPQI.
- 这导致肝炎的增加和肝酶的升高.
结论:
- 鲁泰卡因通过上调CYP1A2和炎症因素,加剧了乙氨基的肝毒性.
- 涉及鲁他卡和乙氨基的药物相互作用需要在临床环境中仔细考虑.
- 这些发现对于安全的药物设计和涉及这些化合物的临床前试验至关重要.
相关概念视频
Phase II Reactions: Acetylation Reactions
209
Acetylation, a phase II biotransformation reaction, introduces an acetyl group to drugs or their metabolites. Acetyltransferase enzymes facilitate this reaction, which resembles α-amino acid conjugation due to the addition of a functional group to the drug molecule.
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
209
Hepatic Drug Excretion: Enterohepatic Cycling
1.5K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.5K
Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems
172
Phase I biotransformation reactions are integral to drug metabolism, predominantly involving oxidative, reductive, and hydrolytic transformations. Chief among these are oxidative reactions, which enhance the hydrophilicity of xenobiotics and introduce polar functional groups to facilitate their elimination from the body.
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
172
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
279
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
279
Anticholinesterase Agents: Poisoning and Treatment
821
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
821
Antiepileptic Drugs: Potassium Channel Activators
157
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
157


